DIANT® Pharma Technology: Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors

The field of genetic medicine is increasingly exploring RNA-based therapeutics delivered via lipid nanoparticles (LNPs) as a robust alternative to traditional viral vectors. While vectors like AAVs offer efficiency and long-term expression, they face limitations, including complex, costly production, restricted payload capacity, and challenges related to immune recognition and safety (such as insertional mutagenesis).

RNA-LNP therapeutics provide a flexible and transient approach, mitigating risks associated with permanent genomic integration and allowing for controlled protein expression and repeated dosing. This platform is versatile, capable of carrying diverse payloads for applications from vaccination to gene editing and protein replacement therapies. The quality and performance of LNPs depend critically on particle uniformity and payload integrity. Continuous flow processes enable reproducible and scalable LNP formation, supporting critical quality attributes like size and encapsulation. Learn how DIANT’s technology provides the precision engineering and process control necessary to reliably generate high-quality, monodispersed LNPs, supporting translation from research to clinical applications.